A randomised trial of the effects of SGLT2 inhibition versus metformin on decline in renal function when used as first line therapy in type 2 diabetes
A randomised trial of the effects of SGLT2 inhibition versus metformin on decline in renal function when used as first line therapy in type 2 diabetes
一项随机试验，比较 SGLT2 抑制与二甲双胍作为 2 型糖尿病一线治疗对肾功能下降的影响
批准号：
nhmrc : 2006893
负责人：
金额：
$381.57万
依托单位国家：
澳大利亚
项目类别：
Clinical Trials and Cohort Studies Grants
财政年份：
2021
资助国家：
澳大利亚
项目状态：
未结题
起止时间：
2021-01-01 至 2025-12-31
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Type 2 diabetes affects 5 in 100 Australians with many going on to develop serious heart and kidney complications. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new type of medicine that may provide benefit when used early in diabetes, but that are currently only used once complications have developed. This study will test the value of SGLT2 inhibitor treatment for kidney protection in Australians with newly diagnosed type 2 diabetes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
基于移动健康技术干预动脉粥样硬化性心血管疾病高危人群的随机对照现场试验：The ASCVD Risk Intervention Trial
-
批准号：81973152
-
项目类别：面上项目
-
资助金额：54.0万元
-
批准年份：2019
-
负责人：胡东生
-
依托单位：
